Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: A prospective, postmarketing observational study

Kousei Yoh, Etsuro Hamaya, Hisashi Urushihara, Noriko Iikuni, Takanori Yamamoto, Masanori Taketsuna, Akimitsu Miyauchi, Hideaki Sowa, Kiyoshi Tanaka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective:To assess changes in quality of life (QOL) and pain in raloxifene-treated Japanese women with postmenopausal osteoporosis. Research design and methods:This prospective, postmarketing observational study was conducted at 60 Japanese hospitals from September 2007 to February 2009 and included Japanese women with postmenopausal osteoporosis who were new to standard treatment with raloxifene (60mg/day). Primary outcome measures (QOL and pain) were assessed using the Short Form-8 (SF-8), European Quality of Life Instrument (EQ-5D), osteoporosis-specific Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), a visual analogue scale (VAS-pain), and a pain frequency survey. Assessments were performed at baseline and 8 (except JOQOL) and 24 weeks after first administration of raloxifene. Adverse drug reactions were recorded. Japan Pharmaceutical Information Center registration number: JapicCTI-070465. Results:A total of 506 participants, mean (±standard deviation [SD]) age=70.7±8.7 years, completed 1 follow-up assessment and were included in the analyses. All QOL scores increased from baseline during follow-up. All SF-8 domain scores increased significantly from baseline after 8 and 24 weeks (P<0.001). Mean (±SD) EQ-5D scores increased significantly from baseline (0.70±0.17) by 0.05±0.15 after 8 weeks and 0.07±0.17 after 24 weeks (P<0.001). The mean (±SD) total JOQOL score increased significantly from baseline (66.8±16.5) by 3.8±11.3 after 24 weeks (P<0.001). The percentage of participants with a 20mm reduction in VAS-pain was 32.6% (120/368) and 39.5% (115/291) after 8 and 24 weeks, respectively. The frequency of pain reported by participants decreased after 8 and 24 weeks. Forty adverse drug reactions were reported by 34 participants. Limitations:Limitations include the lack of a control group, the possibility of the changes being due to the natural disease course, and potential selection bias. Conclusions:Our findings suggest that standard treatment with raloxifene improves QOL and relieves pain in Japanese women with postmenopausal osteoporosis in a real-world clinical setting.

Original languageEnglish
Pages (from-to)1757-1766
Number of pages10
JournalCurrent Medical Research and Opinion
Volume28
Issue number11
DOIs
Publication statusPublished - 2012 Nov
Externally publishedYes

Fingerprint

Postmenopausal Osteoporosis
Observational Studies
Quality of Life
Pain
Osteoporosis
Drug-Related Side Effects and Adverse Reactions
Information Centers
Raloxifene Hydrochloride
Selection Bias
Pain Measurement
Japan
Research Design
Outcome Assessment (Health Care)
Control Groups
Surveys and Questionnaires
Therapeutics

Keywords

  • EQ-5D
  • Japanese postmenopausal osteoporosis
  • JOQOL
  • Quality of life
  • Raloxifene
  • SF-8
  • VAS

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis : A prospective, postmarketing observational study. / Yoh, Kousei; Hamaya, Etsuro; Urushihara, Hisashi; Iikuni, Noriko; Yamamoto, Takanori; Taketsuna, Masanori; Miyauchi, Akimitsu; Sowa, Hideaki; Tanaka, Kiyoshi.

In: Current Medical Research and Opinion, Vol. 28, No. 11, 11.2012, p. 1757-1766.

Research output: Contribution to journalArticle

Yoh, Kousei ; Hamaya, Etsuro ; Urushihara, Hisashi ; Iikuni, Noriko ; Yamamoto, Takanori ; Taketsuna, Masanori ; Miyauchi, Akimitsu ; Sowa, Hideaki ; Tanaka, Kiyoshi. / Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis : A prospective, postmarketing observational study. In: Current Medical Research and Opinion. 2012 ; Vol. 28, No. 11. pp. 1757-1766.
@article{253579c7e0dc4c42825705a97c76a6e5,
title = "Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: A prospective, postmarketing observational study",
abstract = "Objective:To assess changes in quality of life (QOL) and pain in raloxifene-treated Japanese women with postmenopausal osteoporosis. Research design and methods:This prospective, postmarketing observational study was conducted at 60 Japanese hospitals from September 2007 to February 2009 and included Japanese women with postmenopausal osteoporosis who were new to standard treatment with raloxifene (60mg/day). Primary outcome measures (QOL and pain) were assessed using the Short Form-8 (SF-8), European Quality of Life Instrument (EQ-5D), osteoporosis-specific Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), a visual analogue scale (VAS-pain), and a pain frequency survey. Assessments were performed at baseline and 8 (except JOQOL) and 24 weeks after first administration of raloxifene. Adverse drug reactions were recorded. Japan Pharmaceutical Information Center registration number: JapicCTI-070465. Results:A total of 506 participants, mean (±standard deviation [SD]) age=70.7±8.7 years, completed 1 follow-up assessment and were included in the analyses. All QOL scores increased from baseline during follow-up. All SF-8 domain scores increased significantly from baseline after 8 and 24 weeks (P<0.001). Mean (±SD) EQ-5D scores increased significantly from baseline (0.70±0.17) by 0.05±0.15 after 8 weeks and 0.07±0.17 after 24 weeks (P<0.001). The mean (±SD) total JOQOL score increased significantly from baseline (66.8±16.5) by 3.8±11.3 after 24 weeks (P<0.001). The percentage of participants with a 20mm reduction in VAS-pain was 32.6{\%} (120/368) and 39.5{\%} (115/291) after 8 and 24 weeks, respectively. The frequency of pain reported by participants decreased after 8 and 24 weeks. Forty adverse drug reactions were reported by 34 participants. Limitations:Limitations include the lack of a control group, the possibility of the changes being due to the natural disease course, and potential selection bias. Conclusions:Our findings suggest that standard treatment with raloxifene improves QOL and relieves pain in Japanese women with postmenopausal osteoporosis in a real-world clinical setting.",
keywords = "EQ-5D, Japanese postmenopausal osteoporosis, JOQOL, Quality of life, Raloxifene, SF-8, VAS",
author = "Kousei Yoh and Etsuro Hamaya and Hisashi Urushihara and Noriko Iikuni and Takanori Yamamoto and Masanori Taketsuna and Akimitsu Miyauchi and Hideaki Sowa and Kiyoshi Tanaka",
year = "2012",
month = "11",
doi = "10.1185/03007995.2012.736860",
language = "English",
volume = "28",
pages = "1757--1766",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis

T2 - A prospective, postmarketing observational study

AU - Yoh, Kousei

AU - Hamaya, Etsuro

AU - Urushihara, Hisashi

AU - Iikuni, Noriko

AU - Yamamoto, Takanori

AU - Taketsuna, Masanori

AU - Miyauchi, Akimitsu

AU - Sowa, Hideaki

AU - Tanaka, Kiyoshi

PY - 2012/11

Y1 - 2012/11

N2 - Objective:To assess changes in quality of life (QOL) and pain in raloxifene-treated Japanese women with postmenopausal osteoporosis. Research design and methods:This prospective, postmarketing observational study was conducted at 60 Japanese hospitals from September 2007 to February 2009 and included Japanese women with postmenopausal osteoporosis who were new to standard treatment with raloxifene (60mg/day). Primary outcome measures (QOL and pain) were assessed using the Short Form-8 (SF-8), European Quality of Life Instrument (EQ-5D), osteoporosis-specific Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), a visual analogue scale (VAS-pain), and a pain frequency survey. Assessments were performed at baseline and 8 (except JOQOL) and 24 weeks after first administration of raloxifene. Adverse drug reactions were recorded. Japan Pharmaceutical Information Center registration number: JapicCTI-070465. Results:A total of 506 participants, mean (±standard deviation [SD]) age=70.7±8.7 years, completed 1 follow-up assessment and were included in the analyses. All QOL scores increased from baseline during follow-up. All SF-8 domain scores increased significantly from baseline after 8 and 24 weeks (P<0.001). Mean (±SD) EQ-5D scores increased significantly from baseline (0.70±0.17) by 0.05±0.15 after 8 weeks and 0.07±0.17 after 24 weeks (P<0.001). The mean (±SD) total JOQOL score increased significantly from baseline (66.8±16.5) by 3.8±11.3 after 24 weeks (P<0.001). The percentage of participants with a 20mm reduction in VAS-pain was 32.6% (120/368) and 39.5% (115/291) after 8 and 24 weeks, respectively. The frequency of pain reported by participants decreased after 8 and 24 weeks. Forty adverse drug reactions were reported by 34 participants. Limitations:Limitations include the lack of a control group, the possibility of the changes being due to the natural disease course, and potential selection bias. Conclusions:Our findings suggest that standard treatment with raloxifene improves QOL and relieves pain in Japanese women with postmenopausal osteoporosis in a real-world clinical setting.

AB - Objective:To assess changes in quality of life (QOL) and pain in raloxifene-treated Japanese women with postmenopausal osteoporosis. Research design and methods:This prospective, postmarketing observational study was conducted at 60 Japanese hospitals from September 2007 to February 2009 and included Japanese women with postmenopausal osteoporosis who were new to standard treatment with raloxifene (60mg/day). Primary outcome measures (QOL and pain) were assessed using the Short Form-8 (SF-8), European Quality of Life Instrument (EQ-5D), osteoporosis-specific Japanese Osteoporosis Quality of Life Questionnaire (JOQOL), a visual analogue scale (VAS-pain), and a pain frequency survey. Assessments were performed at baseline and 8 (except JOQOL) and 24 weeks after first administration of raloxifene. Adverse drug reactions were recorded. Japan Pharmaceutical Information Center registration number: JapicCTI-070465. Results:A total of 506 participants, mean (±standard deviation [SD]) age=70.7±8.7 years, completed 1 follow-up assessment and were included in the analyses. All QOL scores increased from baseline during follow-up. All SF-8 domain scores increased significantly from baseline after 8 and 24 weeks (P<0.001). Mean (±SD) EQ-5D scores increased significantly from baseline (0.70±0.17) by 0.05±0.15 after 8 weeks and 0.07±0.17 after 24 weeks (P<0.001). The mean (±SD) total JOQOL score increased significantly from baseline (66.8±16.5) by 3.8±11.3 after 24 weeks (P<0.001). The percentage of participants with a 20mm reduction in VAS-pain was 32.6% (120/368) and 39.5% (115/291) after 8 and 24 weeks, respectively. The frequency of pain reported by participants decreased after 8 and 24 weeks. Forty adverse drug reactions were reported by 34 participants. Limitations:Limitations include the lack of a control group, the possibility of the changes being due to the natural disease course, and potential selection bias. Conclusions:Our findings suggest that standard treatment with raloxifene improves QOL and relieves pain in Japanese women with postmenopausal osteoporosis in a real-world clinical setting.

KW - EQ-5D

KW - Japanese postmenopausal osteoporosis

KW - JOQOL

KW - Quality of life

KW - Raloxifene

KW - SF-8

KW - VAS

UR - http://www.scopus.com/inward/record.url?scp=84868675804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868675804&partnerID=8YFLogxK

U2 - 10.1185/03007995.2012.736860

DO - 10.1185/03007995.2012.736860

M3 - Article

C2 - 23035693

AN - SCOPUS:84868675804

VL - 28

SP - 1757

EP - 1766

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 11

ER -